FTL provides capital to companies engaged in the most profound and significant technological advances in the world.
To reach their goals requires risk, guts, and capital—often a great deal more capital than is traditionally available from venture capitalists.
We invest in cutting-edge companies that are developing the next generation of market-leading products and life-saving therapies.
FTL’s flagship Biotechnology Fund created the Contingent Capital Commitment to revolutionize the financing of Phase III clinical trials. By absorbing the risk of the most capital intensive part of the biotech research process and lowering the cost of capital, FTL aims to enable a greater number of people to ultimately benefit from treatments they would not otherwise access.